Atzumi

News

More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi has been given the go-ahead by the agency.

News

Electra Therapeutics has moved ahead with plans for an IPO, seeking to raise funds for its drug for the rare and life-threatening disease sHLH.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.